Sonnet BioTherapeutics Holdings Inc

0.00 (+0.93%)
Earnings Announcements

Sonnet Biotherapeutics Announces Results From Preclinical Combination Study Of SON-1010 With Anti-PD1 Checkpoint Inhibition

Published: 06/09/2022 11:42 GMT
Sonnet BioTherapeutics Holdings Inc (SONN) - Sonnet Biotherapeutics Announces Positive Results From a Preclinical Combination Study of Son-1010 With Anti-pd1 Checkpoint Inhibition.
Sonnet - Tumor Volume Growth Inhibition Improvements Observed With the Combination of Son-1010 and a Commercially Available Anti-pd1 Antibody.
Sonnet - Combination of Son-1010 With Anti-pd1 Increased Survival Rate.
Revenue is expected to be $0.05 Million
Adjusted EPS is expected to be -$0.14

Next Quarter Revenue Guidance is expected to be $0.05 Million
Next Quarter EPS Guidance is expected to be -$0.10

More details on our Analysts Page.